Clinical Trials Browser

Phase 2 × Neoplasm, Residual × 30 days × Clear all

NCT03876769 2026-06-02

CASSIOPEIA

Phase 2 Active not recruiting

Burkitt Lymphoma, Neoplasm, Residual

NCT06500273 2026-06-02

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07136077 2026-06-01

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual